Physicians' Academy for Cardiovascular Education

Ticagrelor non-inferior to clopidogrel for bleedings in post-STEMI patients

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, USA - Otavio Berwanger - São Paulo, Brasil

ACC 2018 In patients post-STEMI, treatment with ticagrelor resulted in similar rate of TIMI-bleedings as clopidogrel after 30 days in the TREAT trial.

Educational information

This 3-minute education provides a summary of just presented scientific data, recorded during the ACC 2018. The objective is to provide a brief commentary and potential implications of these findings.


Otavio Berwanger, MD, is a cardiologist and clinical epidemiologist in the Brazilian Clinical Research Institute in São Paulo, Brasil.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: